ZYME - Zymeworks GAAP EPS of -$0.42 misses by $0.10 revenue of $10.03M misses by $6.4M
2024-05-02 16:27:08 ET
More on Zymeworks
- Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data
- Zymeworks Inc. 2023 Q4 - Results - Earnings Call Presentation
- Zymeworks Inc. (ZYME) Q4 2023 Earnings Call Transcript
- Zymeworks Q1 2024 Earnings Preview
- Zymeworks shares sink after company removes CFO Christopher Astle